Edwards Lifesciences (EW) Stock Forecast & Price Target

Edwards Lifesciences is experiencing expanding operating margins, which have improved by 100 basis points, supported by a favorable foreign exchange benefit, aligning with its long-term growth strategy targeting approximately 10% annual sales growth excluding foreign exchange impacts. The company's commitment to advancing structural heart therapies positions it well for future revenue increases, particularly with anticipated growth in transcatheter aortic valve replacement (TAVR) procedures, bolstered by optimistic physician feedback on procedure volume growth due to enhanced hospital capacities. Additionally, the launch of the Cordella heart failure monitoring device and the reaffirmation of 2025 sales guidance further indicate a robust growth trajectory and strengthening market presence for Edwards Lifesciences.

Edwards Lifesciences faces several fundamental challenges that contribute to a negative outlook on its stock, including concerns over slower than anticipated growth in its transcatheter aortic valve replacement (TAVR) business and the potential for a smaller total addressable market than investors currently project. The company’s innovation pipeline for minimally invasive heart valve products may also take longer than expected to generate significant sales, further compounded by a challenging regulatory and reimbursement environment that could hinder new technology adoption. Additionally, there are risks from increased competition and macroeconomic factors, which could lead to revenue growth headwinds and negatively impact financial performance forecasts.